论文部分内容阅读
目的:探讨采用肝动脉灌注(HAI)结合吉西他滨全身化疗治疗进展期肝内胆管细胞癌(ICC)的临床效果.方法:选取79例具有可测量病灶的进展期ICC患者采用随机数字表法分为试验组(39例)与对照组(40例),试验组采取HAI(5-FU+顺铂)+吉西他滨静脉给药化疗,对照组采取吉西他滨+顺铂进行全身静脉化疗.两组患者均接受2个疗程治疗,1个月为1个疗程.结果:试验组与对照组的缓解率差异无统计学意义(38.46％vs.20.00％,P>0.05),但试验组获益率明显高于对照组(79.49％vs.60.00％,P0.05), but the benefit rate in study group was significantly higher than that in control group (79.49％vs. 60.00％, P<0.05). The levels of tumor biomarkers were significantly decreased in both groups after treatment compared with their pretreatment levels, but their decreasing amplitudes were significantly greater in study group than those in control group (all P0.05), but the 3-year survival rate in study group was significantly higher than that in control group (23.68％ vs. 7.50％, P0.05). Conclusion: HAI combined with systemic intravenous gemcitabine chemotherapy for advanced intrahepatic cholangiocarcinoma patients can achieve relatively good short-term effects and increased long-term survival.